National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 34 of 41
HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru
NCT00023582
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
NCT00001058
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
NCT00000736
Human Immune Responses Smallpox
NCT00068198
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
NCT00000844
A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy
NCT00000969
Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women
NCT00125983
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
NCT00000661
Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy
NCT00000831
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
NCT00000737
A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS
NCT00000674
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
NCT00001026
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
NCT00001055
Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination
NCT00005758
A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
NCT00026611
Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study
NCT00000787
Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
NCT00111605
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
NCT00000829
The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months
NCT00006279
A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)
NCT00000958
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
NCT00001003
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
NCT00000725
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
NCT00000859
A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease
NCT00000880
Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
NCT00050271
Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs
NCT00050921
A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)
NCT00001009
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
NCT00000920
A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
NCT00000782
Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
NCT00000728
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
NCT00001085
Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)
NCT00000676
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
NCT00000838
Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants
NCT00038480
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
NCT00001090
Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.
NCT00000830
Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
NCT00001118
Study of Anti-HIV Therapy Intensification
NCT00034086
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
NCT00028327
A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts
NCT00038688
A Blood Test to Look at Cells of the Immune System in Healthy Children
NCT00001109
A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)
NCT00001006
Long-Term Effects of HIV Exposure and Infection in Children
NCT00006304
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
NCT00000865
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
NCT00000663
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
NCT00096850
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
NCT00000888
Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women
NCT00017797
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
NCT00000657
Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine
NCT00000828
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.